Vimarsana
Biggest News Aggregation in the World

Page 12 - Erick Rowinsky News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Erick Rowinsky. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Erick Rowinsky Today - Breaking & Trending Today

Profund Advisors LLC Boosts Position in Biogen Inc. (NASDAQ:BIIB) - Vimarsana News

Profund Advisors LLC Boosts Position in Biogen Inc. (NASDAQ:BIIB)

Profund Advisors LLC grew its stake in Biogen Inc. (NASDAQ:BIIB – Free Report) by 26.6% during the 3rd quarter, HoldingsChannel reports. The fund owned 17,041 shares of the biotechnology company’s stock after purchasing an additional 3,584 shares during the quarter. Profund Advisors LLC’s holdings in Biogen were worth $4,380,000 as of its most recent SEC […]

Biogen's (BIIB) "Overweight" Rating Reiterated at Cantor Fitzgerald - Vimarsana News

Biogen's (BIIB) "Overweight" Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Biogen (NASDAQ:BIIB – Free Report) in a research note released on Tuesday, Benzinga reports. Cantor Fitzgerald currently has a $311.00 price target on the biotechnology company’s stock. Several other equities research analysts have also recently issued reports on BIIB. Wells Fargo & Company cut Biogen from […]

Biogen's (BIIB) Overweight Rating Reaffirmed at Cantor Fitzgerald - Vimarsana News

Biogen's (BIIB) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Biogen (NASDAQ:BIIB – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. The firm currently has a $311.00 target price on the biotechnology company’s stock. Several other research analysts have also recently issued reports on BIIB. Stifel Nicolaus dropped their price target […]

Biogen (NASDAQ:BIIB) PT Lowered to $277.00 at Mizuho - Vimarsana News

Biogen (NASDAQ:BIIB) PT Lowered to $277.00 at Mizuho

Biogen (NASDAQ:BIIB – Get Free Report) had its price target cut by Mizuho from $355.00 to $277.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Mizuho’s price objective indicates a potential upside of 25.31% from the stock’s previous close. Other […]

Source: wkrb13.com
Fmr LLC Sells 1,279,470 Shares of Biogen Inc. (NASDAQ:BIIB) - Vimarsana News

Fmr LLC Sells 1,279,470 Shares of Biogen Inc. (NASDAQ:BIIB)

Fmr LLC lowered its stake in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 48.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,361,051 shares of the biotechnology company’s stock after selling 1,279,470 shares during the quarter. Fmr LLC […]